Dr. Jan Lundberg, MD, PhD

Dr. Jan Lundberg, MD, PhD joined Image Analysis Group (IAG) in 2018 as Chair of the Scientific Advisory Board and also serves as a Non-Executive Director on IAG's corporate board. With over 22 years of experience in global pharmaceutical R&D, Dr. Lundberg brings invaluable expertise to IAG's scientific strategy and partnerships. In his role at IAG, Dr. Lundberg leads the distinguished board of in-house scientists, imaging experts, and academic collaborators. He works closely with biotech and pharma partners, leveraging his extensive experience in drug discovery and development to provide critical assessments of novel therapeutic agents and strategic positioning to maximize their chances of success. Dr. Lundberg's contributions to IAG's strategy include: Guiding IAG's scientific vision as a powerhouse in the industry Driving partnerships with major pharmaceutical companies Supporting IAG's global expansion efforts Advising on the use of advanced imaging technologies across therapeutic areas His expertise in imaging, particularly in areas like amyloid and tau PET imaging for Alzheimer's research, aligns well with IAG's focus on leveraging technology and AI to optimize clinical trials and accelerate drug development. Dr. Lundberg's involvement enhances IAG's ability to provide early drug efficacy assessments, smart patient recruitment, and predictive analysis of advanced treatment manifestations. This supports IAG's mission to de-risk clinical development and deliver lifesaving therapies to patients more quickly. By bringing his vast experience from leadership roles at Eli Lilly, AstraZeneca, and his academic background at Karolinska Institutet, Dr. Lundberg strengthens IAG's position as a unique partner to life sciences companies, helping them navigate the complex landscape of clinical trials and strategic planning in drug development.